BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Research analysts at HC Wainwright boosted their FY2029 earnings per share estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $2.14 per share for the year, up from their prior estimate of $2.05. HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.27. The company had revenue of $145.53 million for the quarter, compared to analysts' expectations of $126.83 million. BioCryst Pharmaceuticals's revenue for the quarter was up 56.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) EPS.
A number of other brokerages have also weighed in on BCRX. JPMorgan Chase & Co. raised their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday. Needham & Company LLC raised their price target on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Tuesday. Wedbush began coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price target for the company. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective on the stock. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $16.22.
View Our Latest Analysis on BCRX
BioCryst Pharmaceuticals Stock Performance
BCRX stock opened at $10.27 on Wednesday. The company's 50 day moving average price is $7.78 and its 200 day moving average price is $7.84. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -16.84 and a beta of 1.08. BioCryst Pharmaceuticals has a fifty-two week low of $5.04 and a fifty-two week high of $11.11.
Institutional Trading of BioCryst Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $33,000. GAMMA Investing LLC grew its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after buying an additional 5,449 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $46,000. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $48,000. Finally, KBC Group NV lifted its position in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after acquiring an additional 4,537 shares during the period. Hedge funds and other institutional investors own 85.88% of the company's stock.
BioCryst Pharmaceuticals Company Profile
(
Get Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
